- Emyria (EMD) has expanded its clinical service, Emerald Clinics, with a second site in Melbourne
- This expansion comes off the back of record patient appointments in January 2021
- The new East Melbourne location is expected to increase patient access to Emerald Clinics as well as support trials planned for Emyria’s first drug development program, EMD-003
- EMD-003 is the company’s first cannabinoid-based medicine, which it is aiming to have approved by the Australia’s Therapeutic Goods Administration
- On market close for the day, Emyria is up 10.7 per cent and is trading at 15.5 cents per share
Emyria (EMD) has expanded its clinical service subsidiary, Emerald Clinics, with a second site in Melbourne.
This expansion comes off the back of record patient appointments in January 2021.
The new East Melbourne site is co-located with Victorian Counselling and Psychological Services (VCPS), a major provider of mental health services across Melbourne. VCPS is home to clinical psychologists, counsellors and psychiatrists.
The East Melbourne location is expected to increase patient access to Emerald Clinics as well as support trials planned for Emyria’s first drug development program, EMD-003.
EMD-003 is the company’s first cannabinoid-based medicine, which Emyria is aiming to have Australia’s Therapeutic Goods Administration approved.
Each Emerald Clinics site collects data with consenting patients, using a bespoke data platform.
Notably, Emyria’s data asset is one of the largest clinical-trial grade data sets in the world and helps improve care for Emerald Clinic’s patients.
“We are pleased to be able to respond to the high patient demand for our clinical care model across Australia with the addition of a new site in Melbourne,” Managing Director, Dr Michael Winlo said.
“The new site is unique in that it is co-located with Victorian Counseling and Psychological Services and offers unique collaboration opportunities with
mental health clinicians including psychologists and psychiatrists,” he added.
The second clinic will open on February 15.
On market close for the day, Emyria is up 10.7 per cent and is trading at 15.5 cents per share.